Bfl-1 (CT) Blocking Peptide

Bfl-1 (CT) Blocking Peptide

Product No.: B484

[product_table name="All Top" skus="B484"]

- -
- -
Target
Bfl-1
Product Type
Blocking Peptide
Alternate Names
Bcl-2-Related Protein A1, Hemopoietic-Specific Early Response Protein

- -
- -
Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Human
Product Concentration
0.2 mg/ml
Amino Acid Location
14 amino acids near the carboxy terminus of human Bfl-1.
Formulation
This peptide is formulated in PBS pH 7.2 (0.01 M Sodium Phosphate, 0.13 M NaCl) containing 0.1% bovine serum albumin and 0.02% sodium azide.
Storage and Handling
Store this peptide in working aliquots at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day Ambient
Amino Acid Sequence
14 amino acids near the carboxy terminus of human Bfl-1.
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.
Background
Bfl-1 peptide is applicable as a control peptide for blocking antibody binding in Western blotting.

Antigen Details

References & Citations

1. Yan M, Wang LC, Hymowitz SG, et al. Two-amino acid molecular switch in an epithelial morphogen that regulates binding to two distinct receptors. Science 2000; 290:523-7. 2. Sinha SK, Zachariah S, Quinones HI, et al. Role of TRAF3 and -6 in the activation of the NF-κB and JNK pathways by X-linked ectodermal dysplasia receptor. J. Biol. Chem. 2002; 277:44953-61. 3. Sinha SK and Chaudhary PM. Induction of apoptosis by X-linked ectodermal dysplasia receptor via a caspase 8-dependent mechanism. J. Biol. Chem. 2004; 41873-81.
- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.